Abstract Retaspimycin hydrochloride (IPI-504), an Hsp90 (heat shock protein 90) inhibitor, has shown activity in multiple preclinical cancer models, such as lung, breast and ovarian cancers. However, its biological effects in gliomas and normal brain derived cellular populations remain unknown. In this study, we profiled the expression pattern of Hsp90a/b mRNA in stable glioma cell lines, multiple glioma-derived primary cultures and human neural stem/progenitor cells. The effects of IPI-504 on cell proliferation, apoptosis, motility and expression of Hsp90 client proteins were evaluated in glioma cell lines. In vivo activity of IPI-504 was investigated in subcutaneous glioma xenografts. Our results showed Hsp90a and Hsp90b expression levels to be patient-specific, higher in highgrade glioma-derived primary cells than in low-grade glioma-derived primary cells, and strongly correlated with CD133 expression and differentiation status of cells. Hsp90 inhibition by IPI-504 induced apoptosis, blocked migration and invasion, and significantly decreased epidermal growth factor receptor levels, mitogen-activated protein kinase and/or Akt activities, and secretion of vascular endothelial growth factor in glioma cell lines. In vivo study showed that IPI-504 could mildly attenuate tumor growth in immunocompromised mice. These findings suggest that targeting Hsp90 by IPI-504 has the potential to become an active therapeutic strategy in gliomas in a selective group of patients, but further research into combination therapies is still needed.
Introduction
Heat shock proteins (HSPs) are a collection of molecules induced by a variety of stresses (such as hypoxia and starvation) and by certain pathological states including cancer [1, 2] . Hsp90 has two major isoforms in humans, Hsp90a and Hsp90b. While Hsp90b is thought to be constitutively expressed, Hsp90a expression is highly inducible by stressful stimuli [3] . As a molecular chaperone, Hsp90 can regulate the conformation and stability of many client proteins including signaling protein kinases [e.g. EGFR, MAPK cascades, Akt kinase], steroid hormone receptors and components of the telomerase complex [4] .
Recently, targeting Hsp90 has been of great interest in cancer therapy, because abnormal levels of Hsp90 have been found in a number of malignancies [5, 6] . To date, there are over 20 drug candidates that target Hsp90 undergoing interventional trials in multiple cancer indications [7, 8] . Among them, 17-allylamino-17-demethoxygeldanamycin (17-AAG) is one of most advanced product candidates, acting through blocking the ATPase activity of Hsp90 by binding into its ATP-binding pocket [9] . 17-AAG has been proven to work in multiple glioma models, but its clinical development was limited by its relative low solubility [9] . In contrast, IPI-504 is the water soluble, hydroquinone hydrochloride salt of 17-AAG [10] , uniquely designed to overcome the therapeutic limitations of earlier HSP90 inhibitors by allowing simple aqueous-based intravenous formulations for clinical administration [11] . In many cancer models IPI-504 has shown to have a much higher activity than 17-AAG. This can be explained by the fact that inside cells, 17-AAG is enzymatically reduced to the hydroquinone (free base of IPI-504) which is a 40-to 60-fold more potent inhibitor of HSP90 than 17-AAG [12] . IPI-504 is currently in clinical trials for patients with non-small cell lung cancer (http:// www.ClinicalTrial.gov).
High-grade gliomas (HGGs) are the most common primary tumors in the central nervous system [13] . For the patients afflicted by the most aggressive and lethal HGG, glioblastoma multiforme (GBM), the prognosis remains poor, with a median survival of only 12-15 months [14] . Over-expression of Hsp90 has been found in GBM [15] and multiple Hsp90 client proteins, such as EGFR [16] , are involved in gliomagenesis. To date, several Hsp90 inhibitors including 17-AAG have shown potential in preclinical GBM models [17] . However, the activity of IPI-504 in HGGs has not been evaluated.
Recent evidence suggested that the progression of HGGs is driven by a small group of glioma stem-like cells (GSCs), aka glioma tumor initiating cells [18, 19] . These GSCs contribute to tumorigenesis and the subsequent development of highly invasive phenotypes, as well as treatment resistance [20] . In this study, we measured and compared the expression pattern of Hsp90a and Hsp90b in stable glioma cell lines, glioma-derived primary cultures which are exhibiting GSC properties, and NSCs. Furthermore, the anti-tumor effect of IPI-504 as a single agent in HGGs was investigated both in vitro and in vivo.
Materials and methods

Reagents and drugs
All chemicals and reagents were obtained from Sigma (MO, USA) otherwise specified. IPI-504 was provided by Infinity Pharmaceuticals.
Cell lines and primary cultures
As described previously [21] , high/low-grade gliomaderived primary cultures were isolated from surgical specimens (Table S1 ). Human NSCs (SC23, SC27, SC30) were derived by Dr. Philip Schwartz [22] . HuTuP01 cells were a gift from Dr. David Panchision [23] . The detailed culture conditions and verification of stem-cell like characteristics were previously published by our group [21, 24] and were included in Supplementary Methods. Early passage cells (both for the NSCs and GSCs) were defined as cultures that were collected and analyzed in the first four passages.
Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was extracted using RNeasy Mini Kit (Qiagen, MD, USA), and cDNA was generated using the iScript TM cDNA Synthesis Kit (Bio-rad, CA, USA). Quantitative PCR reactions (iQ TM SYBR Green Supermix, Bio-rad) were conducted using a Bio-Rad CFX96 Real-time System, and the gene expression levels were normalized to those of ACTB. The primer sequences were shown in Supplementary Methods.
Antibodies for western blotting
Antibodies used were Hsp90 (ab1429, Abcam, MA, USA), EGFR (ab2430-1, Abcam), Phospho-Erk1/2 Pathway Sampler Kit (#9911, Cell Signaling, MA, USA), p44/42 MAPK (Erk1/2) (#9271, Cell Signaling), Phospho-AKT (Ser473) (#9271, Cell Signaling), pan-Akt (ab8805, Abcam) and b-actin (NB600-501, Novus, CO, USA).
Magnetic cell sorting CD133? cell selection was performed using CD133 MicroBead Kit (Miltenyi Biotec Inc., CA, USA) as indicated by manufacturer.
Cell proliferation assay
The viability of cells was determined with the Cell Proliferation Kit II (XTT) (Roche, IN, USA). The metabolic conversion of XTT to formazan by live cells was determined by measuring absorbance at 450 nm and expressed as percentage of control.
Flow cytometry
Cells were harvested and fixed in ice-cold 70 % ethanol, and then treated with RNase (10 lg/ml) and stained with propidium iodide (2.5 lg/ml) for 30 min at 37 AE C. Cell cycle analysis was performed on an FACScan flow cytometer (BD Biosciences, NJ, USA) and analyzed using the FlowJo software (Tree Star, Inc., OR, USA).
TUNEL assay
The DNA fragmentation in cells treated by IPI-504 was identified with the NeuroTACS TM II In Situ Apoptosis Detection Kit (Trevigen Inc., MD, USA) according to the manufacturer's instruction.
Invasion assay
Invasion assay was performed using BD BioCoat TM Matrigel TM Invasion Chamber with an 8 lm PET membrane (BD Biosciences). Cells were seeded in medium without serum, and medium containing 1.5 % FBS was used as chemo-attractant. After an incubation of 24 h at 37°C, non-invasive cells were removed and invading cells were fixed with 100 % methanol. Cells were then stained in hematoxylin.
Immunocytochemistry
Cells were fixed with 10 % buffered formalin, incubated with 0.5 % Triton X-100 in PBS for 10 min, and then blocked with 3 % hydrogen peroxide. The avidin-biotin immunoperoxidase reaction (Vector Laboratories, CA, USA) was performed using an EGFR antibody (28-0005, Invitrogen, NY, USA). Cells were counterstained with hematoxylin.
VEGF ELISA
Cells were grown in serum-free medium for 1 day and then treated with 1 lM of IPI-504 in reduced serum medium (3 % FBS) for 24 h. The conditioned medium was collected and VEGF levels were analyzed by Human VEGF Immunoassay kit (R&D Systems, MN, USA).
Subcutaneous xenograft implantation and response to IPI-504 treatment
Female athymic mice (nu/nu genotype, Balb/c background, 6 to 8 weeks old) were used to implant D-54MG and U-251 xenografts maintained at the Preston Robert Tisch Brain Tumor Center (Duke University of Medical Center, USA) [25] . Groups of mice (9 or 10 mice in each group) were treated by IPI-504 or saline when the median tumor volumes were on average 250 mm 3 . IPI-540 was injected intraperitoneally with the schedules as indicated in Table 1 for  D-54MG xenografts (and the Table S2 for U-251). Tumors were measured twice weekly with hand-held calipers. The endpoint was defined as the number of days needed to reach a tumor volume five times greater than that measured at the start of the treatment. Growth delay, expressed as T-C, was defined as the difference in days between the median time required for tumors in treated (T) and control (C) animals.
Tumor regression was defined as a decrease in tumor volume over two successive measurements.
Statistical analysis
Statistical analyses for the in vitro experiments were prepared using GraphPad Prism version 5.04 (GraphPad Software Inc., La Jolla, CA, USA). All values were presented as mean ± SE of the mean (SEM). Statistical significance was determined with unpaired t test. p \ 0.05 was considered significant. For the animal experiments, statistical analysis was performed using the SAS statistical analysis program, the Wilcoxon rank order test for growth delay, and Fisher's exact test for tumor regression as previously described [26] .
Results
The expression pattern of Hsp90a/b in stable glioma cell lines, low/high-grade glioma-derived GSCs and normal NSCs
We profiled Hsp90a and Hsp90b mRNA levels using four stable glioma cell lines (D-54, LN-229, U-251 and U-87), nineteen diverse histological GSCs derived from glioma patients (Table S1 ) and three NSCs (SC23, SC27 and SC30). Overall, compared to stable cell lines, low-grade glioma-derived GSCs and NSCs, the Hsp90a/90b expression was much higher in some of HGG-derived GSCs, such as DB33 (Grade III) and DB32/34 (GBM) ( Fig. 1 ; Table  S1 ). However, the Hsp90a/90b expression varied significantly between specimens within the same pathological diagnosis, raising the question of the role of Hsp90a and Hsp90b as prognostic indicator. As shown in the Table S1 (survival data), the GBM patients with the lowest Hsp90a/ b levels (DB37 and DB50) had a better prognosis (13 and 14 month survival, respectively) compared to patients with the highest Hsp90a/b levels (DB32 and DB34; 9 month survival). The similar results could also be found in Grade III patients-the patient with the highest Hsp90a levels (DB33) and the poorest prognosis. Those data suggested a preliminary possible association between clinical prognosis and Hsp90a/b expression. Hsp90 over-expression is already reported to correlate with poor prognosis in breast cancer and gastric cancer patients but further adequate investigation in a larger number of glioma specimens is required to confirm our findings.
Hsp90a/b mRNA levels correlate with differentiation status and CD133 mRNA levels in gliomas and NSCs Hsp90 plays a role in embryonic cell differentiation [27, 28] , and long-term in vitro expansion of stem/precursor J Neurooncol (2014) 120:473-481 475 cells may induce neuronal differentiation [29] . Our previous work [21] demonstrated that during continued in vitro expansion, DB32 and HuTuP01 GSCs underwent differentiation indicated by significantly decrease in the mRNA levels of CD133, a well-established stem cell marker in the brain. By comparing with early and late passages of DB32 and HuTuP01 GSCs, that expressed the highest and moderate levels of Hsp90a/b respectively, we found that Hsp90a and Hsp90b dramatically attenuated after continuous expansion ( Fig. 2a and b) , along with down-regulation of Hsp90 protein levels (Fig. 2b) . These data suggested that Hsp90a/b levels are correlated with differentiation status and CD133 expression in GSCs. To further identify the correlation between CD133 and Hsp90, magnetic microbeads were used to separate CD133? and CD133-population from HuTuP01 cells, and the expression of Hsp90a/b was then analyzed. As shown in Fig. 2c , both Hsp90a and Hsp90b levels were markedly higher in CD133 ? cell population.
Our previous work demonstrated that when DB32 and HuTuP01 cells underwent differentiation by switching culture medium from serum-free stem cell medium (SCM) to serum-containing medium (differentiation medium), CD133 revealed a dramatic decrease [21] . In this study, a significant drop of Hsp90a/b was also detected [ Fig. 2d (left panel) and e]. Interestingly, when HuTuP01 was switched back to SCM (leading to a less differentiated state), both Hsp90a and Hsp90b increased again (Fig. 2d,  right panel) . Furthermore, when D-54MG cells were cultured in SCM which allowed cells to transit to an undifferentiated stem cell state, as indicated by CD133 upregulation and tumor sphere formation [21] , a significant elevation on Hsp90a/b mRNA was found (Fig. 2f) .
We also checked the expression pattern of Hsp90a/b in normal NSCs undergoing differentiation. When SC27 cells underwent continuous expansion, the NSC markers CD133 and nestin dramatically decreased (Fig. 2g, left panel) . In contrast with our results obtained from GSCs, SC27 T-C The difference in days between the median time required for tumors in treated (T) and control (C) animals to reach a volume five times greater than that measured at the start of treatment
Tumor regression The decrease in tumor volume over two successive measurements U-251  D-54  DB17  DB26  DB32  DB34  DB37  SC23  SC27  SC30  LN229  U-87  DB29  DB30  DB43  DB44  DB33  DB47  DB39  HuTuP01  DB51  DB55  DB49  DB50  DB53  DB54 glioma cell lines Grade II Grade III showed elevated expression of Hsp90a/b in late passage cells (Fig. 2g, right panel) . The question of potential neurotoxicity of new drugs is becoming more urgent, as more and more glioma patients are becoming long-term survivors. To further explore the clinical significance of these data, we exposed both NSC (SC27) and GSC (HuTuP01) cells to graded concentrations of IPI-504, a novel Hsp90 inhibitor. The SC27 cells which have low Hsp90 constitutive expression continued to proliferate at doses toxic to HuTuP01 cells (Fig. 2h) , suggesting that IPI-504 might selectively target the GSCs while not eradicating the NSCs.
GBM NSCs
Taken together, our results suggest that the levels of Hsp90a/b correlate with differentiation status in both GSCs and NSCs, but displaying different expression patterns, which might protect NSCs from potential Hsp90 inhibitionrelated toxicity.
IPI-504 inhibits proliferation and induces apoptosis in glioma cells
We next focused on the effect of IPI-504 on glioma cells. The anti-proliferation effect of IPI-504 indicated by decreased S phase cells was accompanying with increased sub-G1
HuTuP01
Normalized fold expression population of cells (Fig. 3a) , and induction of fragmented DNA of the apoptotic cells (Fig. 3b) in a dose/time-dependent manner. Meanwhile, a significant up-regulation of cleaved PARP was detected in IPI-504 treated cells (Fig. 3c) .
We next compared the toxicity of 17-AAG and IPI-504 on glioma cells. While IC50 was 0.045 lM and 0.011 lM (D-54MG and U-251MG, respectively) for IPI-504 treatment, IC50 was 0.143 lM and 5.87 lM in 17-AAG treated cells (Fig. S1) .
GBM tumors are notoriously resistant to treatment, and new treatments are needed both for newly-diagnosed, chemotherapy naïve patients as well as for the patients that already developed resistance to the first-line chemotherapy treatment (temozolomide). Next, we used two glioma cell lines (D-54MG and U-251MG) and two temozolomideresistant (TR) lines (D-54TR and U-251TR [25] ), to investigate the anti-tumor effect of IPI-504 in vitro. As shown in Fig. S2a , both the parental and TR cells were sensitive to IPI-504, and their proliferation was dramatically decreased in a dose-dependent manner, while TR cells maintained their tolerance to temozolomide [25] .
Hsp90 inhibition by IPI-504 suppresses migration and invasion of glioma cells, and displays doseand time-dependent effects on Hsp90 client proteins Since the invasive behavior of HGGs contributes to their poor prognosis [30] , the role of IPI-504 on cell invasion was measured using the Matrigel invasion assay (Fig. 4a) . In both D-54MG and U-251MG cells, the capability of invasion was robustly inhibited (p \ 0.001). Wound closure assay (Fig. S2b) further confirmed these data. While the gap was only partially filled in IPI-504 treated cells, even after 24 h, control cells were able to migrate in and fill up the gap within 18 h.
Next, we investigated the underlying mechanism of IPI-504 function through Hsp90 client proteins [4] , such as EGFR which is constitutively upregulated in GBM [16] . D-54MG and U-251MG cells were treated with IPI-504 and immunohistochemistry staining was then used to evaluate the expression of EGFR. As shown in Fig. 4b , IPI-504 decreased the expression of EGFR in both cell lines tested. Western blotting was then used to evaluate the expression levels of EGFR and some other Hsp90 client proteins. As shown in Fig. 4c , IPI-504 treatment down-regulated the expression of EGFR, phosphorylation of MAPKs and AKT, and total levels of AKT, indicating that the anti-tumor effect of IPI-504 was associated with Hsp90 client protein degradation.
VEGF, a potent angiogenic molecule, is highly expressed in glioblastoma [31] , and the secretion of VEGF by tumor cells depends heavily on EGFR-mediated signaling [32] . Using VEGF ELISA, we examined the secretion of VEGF in IPI-504 treated cells. As shown in Fig. 4d , a significant reduction of VEGF was found in glioma cells upon IPI-504 treatment. To evaluate the anti-tumor activity of IPI-504 in vivo, D-54MG tumor xenografts were injected subcutaneously into the immunodeficient mice. As shown in Table, in two independent experiments, IPI-504 showed a trend to delay tumor growth with 2.49 and 3.45 days respectively when compared with saline-treated tumors (p \ 0.1). In addition, 21 % of the mice (4 out of 19) used in this study displayed tumor regression, indicating an anti-tumor effect of IPI-504 in vivo. The same study was performed using U-251MG tumor xenografts. However, IPI-504 revealed a limited anti-tumor activity in U-251MG xenografts (Table S2) . We next evaluated the direct effects of IPI-504 in tumor tissues harvested from the D-54MG xenograft model. Although the drug down-regulated the majority of Hsp90 client proteins in tissue culture, results varied from one tumor to another and no consistent effects were noted in xenograft tissues, except up-regulation of Hsp70 (Fig. S3) . Similar results were previously reported by another group in a pancreatic cancer xenograft study [33] .
Discussion
Our study profiles the expression pattern of Hsp90a and Hsp90b in human GSCs and NSCs (Fig. 1) . It further demonstrates that Hsp90a/b mRNA levels correlate with differentiation status and CD133 mRNA levels in humanderived GSCs (Fig. 2a-e) . Those data are consistent with a previously published article, which Hsp90 showed remarkably high expression in undifferentiated human embryonal carcinoma cells and dramatic down-regulation during in vitro cellular differentiation [27] . Unlike the differentiation pattern seen in GSCs, the Hsp90a/b levels are up-regulated when NSCs are undergoing differentiation (Fig. 2g) .
Since the lineage connection between NSCs and GSCs is not established, the variance of Hsp90a/b expression pattern during differentiation in GSCs and NSCs requires further investigation.
Another difference between NSCs and GSCs is their divergent response to Hsp90 inhibition. Hsp90 inhibition by IPI-504 selectively targets GSCs while not affecting NSC survival (Fig. 2h) , suggesting a favorable therapeutic profile with limited neurotoxicity for Hsp90 inhibitors. The response of GSCs and NSCs to Hsp90 inhibitors has also been investigated recently by a few other laboratories, with similar results. For example, murine GSCs derived from normal NSCs are more susceptible to 17-AAG than wildtype NSCs [17] . In addition, a subset of GSCs having highexpressing Olig2 exhibits greater sensitivity to a novel Hsp90 inhibitor NVP-HSP990 [34] . Since more and more glioma patients are becoming long-term survivors, seeking new drugs with limited neurotoxicity is becoming more urgent.
The strong correlation between Hsp90 expression profile and tumor progression [7, 8] suggests that Hsp90 may be a potential biomarker. While Hsp90 over-expression is already reported to correlate with poor prognosis in breast cancer and gastric cancer patients [5, 6] , our study implies that the Hsp90 over-expression may be a poor prognostic indicator for gliomas. The Hsp90a/b levels of GSCs seem to correlate with poor prognosis in high-grade glioma patients, as the GBM patients with the lowest Hsp90a/b levels have a better prognosis compared to patients with the highest Hsp90a/b levels (Table S1 , survival data). However, with the limited patient number included in our study, a further and more extensive investigation is required.
It has been reported that 17-AAG is able to inhibit the intracranial tumor growth of both glioma cell lines and GSCs as a single agent [17, 35] . In our study, IPI-504 not only displays the anti-glioma activity in vitro by suppressing proliferation and inhibiting migration and invasion (Figs. 3 and 4 ), but shows a much stronger antiproliferation effect than 17-AAG (Fig. S1 ). However, IPI-504 has a modest anti-tumor influence in vivo (Table S2) , similar with a previous report that IPI-504 exerted a cytostatic effect on mantle cell lymphoma (MCL) cell lines, but only slightly inhibited tumor growth in vivo [36] . Although IPI-504 has limited activity as a single agent in our glioma model, it has a promising effect in other in vivo models as a combination therapy, including Kras mutant non-small cell lung cancer [37] , and HER2-positive trastuzumab-resistant breast cancer [38] . The possibility of a combinational strategy of IPI-504 with other drugs in GBM is at the core of our future plans.
In summary, this study provides the first profile of the expression pattern of Hsp90a/b in GSCs and NSCs, and shows that human GSCs are particularly susceptible to Hsp90 inhibition. Our data suggests that Hsp90a and Hsp90b strongly relate to the differentiation status of glioma and/or neural precursor/stem cells. In our glioma models, inhibiting Hsp90 by IPI-504 does exert significant anti-tumor activity in vitro, but modestly alters tumor growth in vivo, implying a combinational strategy with others drugs may be an attractive therapeutic strategy for GBM patients.
